uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
Rambam Hlth Care Campus, Div Infect Dis, Haifa, Israel..
Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel.;Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel..
Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel.;Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel..
Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel.;Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel..
Vise andre og tillknytning
2016 (engelsk)Inngår i: BMJ Open, ISSN 2044-6055, E-ISSN 2044-6055, Vol. 6, nr 4, artikkel-id e009956Artikkel i tidsskrift (Fagfellevurdert) Published
Resurstyp
Text
Abstract [en]

Introduction: The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective and more toxic than modern antibiotics. In vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomised controlled study is necessary for clarification. Methods and analysis: This is a multicentre, investigator-initiated, open-label, randomised controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gram-negative bacteria. The study is being conducted in 6 centres in 3 countries (Italy, Greece and Israel). We include patients with hospital-associated and ventilator-associated pneumonia, bloodstream infections and urosepsis. The primary outcome is treatment success at day 14, defined as survival, haemodynamic stability, stable or improved respiratory status for patients with pneumonia, microbiological cure for patients with bacteraemia and stability or improvement of the Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes include 14-day and 28-day mortality as well as other clinical end points and safety outcomes. A sample size of 360 patients was calculated on the basis of an absolute improvement in clinical success of 15% with combination therapy. Outcomes will be assessed by intention to treat. Serum colistin samples are obtained from all patients to obtain population pharmacokinetic models. Microbiological sampling includes weekly surveillance samples with analysis of resistance mechanisms and synergy. An observational trial is evaluating patients who met eligibility requirements but were not randomised in order to assess generalisability of findings. Ethics and dissemination: The study was approved by ethics committees at each centre and informed consent will be obtained for all patients. The trial is being performed under the auspices of an independent data and safety monitoring committee and is included in a broad dissemination strategy regarding revival of old antibiotics.

sted, utgiver, år, opplag, sider
2016. Vol. 6, nr 4, artikkel-id e009956
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-298702DOI: 10.1136/bmjopen-2015-009956ISI: 000376391400033PubMedID: 27098822OAI: oai:DiVA.org:uu-298702DiVA, id: diva2:947273
Forskningsfinansiär
EU, FP7, Seventh Framework Programme, Health-F3-2011-278348Tilgjengelig fra: 2016-07-07 Laget: 2016-07-06 Sist oppdatert: 2017-11-28bibliografisk kontrollert

Open Access i DiVA

fulltext(916 kB)275 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 916 kBChecksum SHA-512
38ca0e6dcb53e3bc82f556e40d4f9e015bdfc4831b41894bda832486c9ce134b34b3ac1020adca0853bee7ef21747cfa7bedc92e2a182ba1200726c31b4e61f2
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Friberg, Lena E.Kristoffersson, Anders N.

Søk i DiVA

Av forfatter/redaktør
Friberg, Lena E.Kristoffersson, Anders N.
Av organisasjonen
I samme tidsskrift
BMJ Open

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 275 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 530 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf